JESSICA PELLETIER: Open Payments
NPI 1801307475 · PROSPECT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,230 in 158 payments from 19 companies in 2025. Trend: 2023 $2,173 · 2024 $2,717 · 2025 $3,230
Food & beverage: $3,220Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $560 |
| Madrigal Pharmaceuticals | 20 | $484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $411 |
| Gilead Sciences, Inc. | 13 | $276 |
| Janssen Biotech, Inc. | 9 | $228 |
| PFIZER INC. | 12 | $212 |
| Ipsen Biopharmaceuticals, Inc | 8 | $202 |
| Lilly USA, LLC | 10 | $197 |
| Ardelyx, Inc. | 11 | $176 |
| Aimmune Therapeutics, Inc. | 3 | $99 |
Products named: REZDIFFRA, ENTYVIO, RINVOQ, TREMFYA, IQIRVO, OMVOH, IBSRELA, VELSIPITY.
Industry payments across CT — which companies pay providers there.
